Arog Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Dallas TX United States (2010)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2010
NCT00949624
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Arog Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Gastrointestinal Stromal Tumors (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Hematologic Neoplasms (Phase 1)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 20